Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CorMedix Inc. (CRMD)
USD8.19
-0.08 (-0.97%)
US NASDAQ Healthcare Biotechnology
Address
300 Connell Drive 7922
Berkeley Heights, NJ, US
Berkeley Heights, NJ, US
CEO
Joseph Todisco
Website
cormedix.com
IPO
2010-05-13
CIK 1410098 ISIN US21900C3088
Description
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.19
-0.08 (-0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.47
Float Shares
70.44M
Free Float %
89.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.73% | -1.25% | +8.63% | +8.04% | -29.45% | -31.81% | -31.76% | +53.98% | +31.07% | -44.55% | -47.13% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
8.19
Low
13.00
+58.7%
Consensus
14.00
+70.9%
Median
13.50
+64.8%
High
16.00
+95.4%
DCF (Unlevered)
2.51
-69.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
14.00
+70.9%
|
| Last Quarter | 2 |
13.50
+64.8%
|
| Last Year | 7 |
15.43
+88.4%
|
| All Time | 8 |
14.63
+78.6%
|
Quality scores
Altman Z-Score
2.41
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+617.0% ★ Q1'26: +226.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+780.0% ★ Q1'26: +43.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+57.9% Q1'26: +33.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+48.2% ★ Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+37.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+36.4% Q1'26: +34.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.90× ★ Q1'26: 0.57× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
210.1K
est: 261.2K (-19.6%)
|
224.1K
est: 156.5K (+43.2%)
|
329.3K
est: 337.0K (-2.3%)
|
429.8K
est: 645.5K (-33.4%)
|
283.3K
est: 350.5K (-19.2%)
|
239.2K
est: 210.6K (+13.6%)
|
190.9K
est: 124.3K (+53.6%)
|
65.4K
est: 26.2K (+149.3%)
|
—
est: 806.1K (-100.0%)
|
43.47M
est: 40.09M (+8.4%)
|
311.71M
est: 310.12M (+0.5%)
|
308.22M
302.62M – 313.82M
-0.6% YoY
|
282.40M
275.59M – 289.21M
-8.4% YoY
|
353.16M
338.55M – 368.67M
+25.1% YoY
|
435.52M
417.51M – 454.65M
+23.3% YoY
|
586.13M
561.89M – 611.87M
+34.6% YoY
|
| EBITDA |
-18.17M
est: -127.3K (-14,171.5%)
|
-24.62M
est: -76.3K (-32,180.0%)
|
-32.97M
est: -164.2K (-19,978.1%)
|
-26.75M
est: -314.6K (-8,405.0%)
|
-20.93M
est: -170.8K (-12,156.6%)
|
-27.02M
est: -102.6K (-26,228.4%)
|
-29.38M
est: -60.6K (-48,383.5%)
|
-30.05M
est: -12.8K (-234,991.7%)
|
-46.23M
est: -146.2K (-31,523.9%)
|
-18.98M
est: -7.27M (-161.0%)
|
165.13M
est: -56.24M (+393.6%)
|
-55.90M
-56.92M – -54.89M
+0.6% YoY
|
-51.22M
-52.45M – -49.98M
+8.4% YoY
|
-64.05M
-66.86M – -61.40M
-25.1% YoY
|
-78.99M
-82.46M – -75.72M
-23.3% YoY
|
-106.30M
-110.97M – -101.91M
-34.6% YoY
|
| EBIT |
-18.18M
est: -127.7K (-14,141.7%)
|
-24.64M
est: -76.5K (-32,119.4%)
|
-33.00M
est: -164.7K (-19,938.4%)
|
-26.83M
est: -315.5K (-8,403.8%)
|
-21.01M
est: -171.3K (-12,163.6%)
|
-27.16M
est: -102.9K (-26,291.1%)
|
-29.44M
est: -60.8K (-48,355.5%)
|
-30.26M
est: -12.8K (-235,925.3%)
|
-46.30M
est: -155.1K (-29,754.7%)
|
-19.29M
est: -7.71M (-150.1%)
|
150.14M
est: -59.67M (+351.6%)
|
-59.30M
-60.38M – -58.23M
+0.6% YoY
|
-54.34M
-55.65M – -53.03M
+8.4% YoY
|
-67.95M
-70.93M – -65.14M
-25.1% YoY
|
-83.80M
-87.48M – -80.33M
-23.3% YoY
|
-112.77M
-117.73M – -108.11M
-34.6% YoY
|
| Net Income |
-18.19M
est: -182.50M (+90.0%)
|
-24.64M
est: -208.99M (+88.2%)
|
-33.01M
est: -164.84M (+80.0%)
|
-26.83M
est: -123.63M (+78.3%)
|
-16.43M
est: -75.06M (+78.1%)
|
-22.03M
est: -48.27M (+54.4%)
|
-28.21M
est: -46.90M (+39.9%)
|
-29.70M
est: -36.90M (+19.5%)
|
-46.34M
est: -74.54M (+37.8%)
|
-17.93M
est: -30.91M (+42.0%)
|
163.06M
est: 216.42M (-24.7%)
|
41.54M
32.67M – 50.41M
-80.8% YoY
|
30.35M
1.21M – 41.24M
-26.9% YoY
|
67.77M
24.09M – 119.66M
+123.3% YoY
|
93.48M
88.45M – 98.82M
+37.9% YoY
|
159.01M
150.46M – 168.09M
+70.1% YoY
|
| SGA |
10.26M
est: 23.61M (-56.5%)
|
8.88M
est: 14.14M (-37.2%)
|
8.65M
est: 30.45M (-71.6%)
|
8.07M
est: 58.33M (-86.2%)
|
—
est: 31.67M (-100.0%)
|
13.88M
est: 19.03M (-27.1%)
|
16.35M
est: 11.24M (+45.5%)
|
20.01M
est: 2.37M (+743.9%)
|
35.60M
est: 63.51M (-44.0%)
|
58.70M
est: 3.16B (-98.1%)
|
30.17M
est: 24.43B (-99.9%)
|
24.28B
23.84B – 24.72B
-0.6% YoY
|
22.25B
21.71B – 22.79B
-8.4% YoY
|
27.82B
26.67B – 29.05B
+25.1% YoY
|
34.31B
32.89B – 35.82B
+23.3% YoY
|
46.18B
44.27B – 48.21B
+34.6% YoY
|
| EPS |
-2.90
est: -3.10 (+6.5%)
|
-3.25
est: -3.55 (+8.5%)
|
-2.99
est: -2.80 (-6.8%)
|
-1.51
est: -2.10 (+28.1%)
|
-0.68
est: -1.28 (+46.7%)
|
-0.77
est: -0.82 (+6.1%)
|
-0.75
est: -0.80 (+5.9%)
|
-0.74
est: -0.73 (-1.3%)
|
-0.91
est: -0.93 (+1.8%)
|
-0.30
est: -0.38 (+21.9%)
|
2.25
est: 2.68 (-16.1%)
|
0.51
0.41 – 0.63
-80.9% YoY
|
0.21
0.02 – 0.51
-58.7% YoY
|
0.67
0.30 – 1.49
+217.8% YoY
|
1.16
1.10 – 1.23
+73.2% YoY
|
1.98
1.87 – 2.09
+70.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | Citizens | Market Outperform | Market Outperform | Maintain |
| 2026-04-27 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
190.06M
OE per share TTM
2.25
Owner's Yield
31.47%
Maintenance CapEx ratio
40.21%
Maint CapEx / Avg PPE
5.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
74
Total invested
66.51M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Elliott Investment Management L.P. | 7.14M | 4.99% | 7.14M | — | 7.14M | 10.00 | IA, PN | Delaware | 2021-02-11 | ↗ |
| 2 | Elliott International Capital Advisors Inc. | 4.12M | 4.99% | — | 4.12M | — | 10.00 | CO | Delaware | 2019-09-10 | ↗ |
| 3 | Elliott International, L.P. | 4.12M | 4.99% | — | 4.12M | — | 10.00 | PN | Cayman Islands, British West Indies | 2019-09-10 | ↗ |
| 4 | (1) BlackRock, Inc. | 3.51M | 6.40% | 3.48M | — | 3.51M | — | HC | Delaware | 2024-01-29 | ↗ |
| 5 | CVI Investments, Inc. | 2.85M | 4.10% | — | 2.85M | — | — | CO | Cayman Islands | 2018-02-09 | ↗ |
| 6 | Heights Capital Management, Inc. | 2.85M | 4.10% | — | 2.85M | — | — | CO | Cayman Islands | 2018-02-09 | ↗ |
| 7 | The Vanguard Group - 23-1945930 | 2.83M | 5.15% | — | 85.3K | — | — | IA | Pennsylvania | 2024-02-13 | ↗ |
| 8 | Elliott Associates, L.P. | 2.66M | 4.99% | 2.66M | — | 2.66M | 10.00 | PN | Delaware | 2019-09-10 | ↗ |
| 9 | Nomura Global Financial Products, Inc. | 2.00M | 5.30% | — | 2.00M | — | 2.00M | BD | Japan | 2022-02-14 | ↗ |
| 10 | Nomura Holdings, Inc. | 2.00M | 5.30% | — | 2.00M | — | 2.00M | HC | Japan | 2022-02-14 | ↗ |
| 11 | Adam J. Chill | 1.74M | 4.90% | — | 1.74M | — | — | IN | United States | 2015-02-13 | ↗ |
| 12 | Ari Storch | 1.74M | 4.90% | — | 1.74M | — | — | IN | United States | 2015-02-13 | ↗ |
| 13 | Kingsbrook Opportunities GP LLC | 1.74M | 4.90% | — | 1.74M | — | — | OO | Delaware | 2015-02-13 | ↗ |
| 14 | Kingsbrook Opportunities Master Fund LP | 1.74M | 4.90% | — | 1.74M | — | — | PN | Cayman Islands | 2015-02-13 | ↗ |
| 15 | Kingsbrook Partners LP | 1.74M | 4.90% | — | 1.74M | — | — | PN | Delaware | 2015-02-13 | ↗ |
| 16 | Scott Wallace | 1.74M | 4.90% | — | 1.74M | — | — | IN | United States | 2015-02-13 | ↗ |
| 17 | PharmaBio Development Inc. | 1.18M | 10.00% | — | — | — | — | CO | North Carolina | 2011-03-23 | ↗ |
| 18 | LINDSAY A. ROSENWALD, M.D. | 577.2K | 5.00% | 577.2K | — | — | — | IN | UNITED STATES | 2010-12-09 | ↗ |
| 19 | ICS Opportunities, Ltd. | 200.0K | 1.70% | — | 200.0K | — | 200.0K | CO | Delaware | 2012-01-17 | ↗ |
| 20 | Israel A. Englander | 200.0K | 1.70% | — | 200.0K | — | 200.0K | IN | Delaware | 2012-01-17 | ↗ |
| 21 | Millennium International Management GP LLC | 200.0K | 1.70% | — | 200.0K | — | 200.0K | OO | Delaware | 2012-01-17 | ↗ |
| 22 | Millennium International Management LP | 200.0K | 1.70% | — | 200.0K | — | 200.0K | PN | Delaware | 2012-01-17 | ↗ |
| 23 | Millennium Management LLC | 200.0K | 1.70% | — | 200.0K | — | 200.0K | OO | Delaware | 2012-01-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
74
-136 vs prev Q
New positions
15
Closed positions
142
Increased
38
Reduced
18
Put/Call ratio
0.00
Calls held
4.0K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 170.9K +170.9K (+100.0%) | 1.99B +2.0B (+100.0%) | 0.23% +0.225 pp | 0.78% +0.784 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 5.78M +88.1K (+1.5%) | 67.18M +1.0M (+1.5%) | 7.61% -0.767 pp | 0.00% +0.000 pp | USD8.75 +32.9% | 6 qtrs — |
| 3 | DEEP TRACK CAPITAL, LP | 5.27M +4.8M (+954.8%) | 61.34M +55.5M (+954.8%) | 6.95% +6.210 pp | 1.09% +0.931 pp | USD11.63 +0.0% | 2 qtrs — |
| 4 | VANGUARD GROUP INC | 4.50M +521.4K (+13.1%) | 52.32M +6.1M (+13.1%) | 5.93% +0.070 pp | 0.00% +0.000 pp | USD8.10 +43.6% | 28 qtrs — |
| 5 | MARSHALL WACE, LLP | 1.97M -1.5M (-43.4%) | 22.87M -17.5M (-43.4%) | 2.59% -2.524 pp | 0.02% -0.020 pp | USD11.73 -0.9% | 16 qtrs — |
| 6 | STATE STREET CORP | 1.92M +85.2K (+4.6%) | 22.34M +991.3K (+4.6%) | 2.53% -0.173 pp | 0.00% +0.000 pp | USD6.43 +80.9% | 28 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.91M +102.5K (+5.7%) | 22.24M +1.2M (+5.7%) | 2.52% -0.146 pp | 0.00% +0.000 pp | USD6.92 +68.1% | 28 qtrs — |
| 8 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.11M -2.2M (-66.7%) | 12.89M -25.8M (-66.7%) | 1.46% -3.434 pp | 0.16% -0.426 pp | USD11.63 +0.0% | 2 qtrs — |
| 9 | ALYESKA INVESTMENT GROUP, L.P. | 850.0K -413.0K (-32.7%) | 9.89M -4.8M (-32.7%) | 1.12% -0.740 pp | 0.03% -0.017 pp | USD12.04 -3.4% | 3 qtrs — |
| 10 | GOLDMAN SACHS GROUP INC | 828.8K +598.0K (+259.1%) | 9.64M +7.0M (+259.1%) | 1.09% +0.752 pp | 0.00% +0.001 pp | USD10.56 +10.1% | 11 qtrs — |
| 11 | OBERWEIS ASSET MANAGEMENT INC/ | 805.1K +19.4K (+2.5%) | 9.36M +225.8K (+2.5%) | 1.06% -0.096 pp | 0.34% -0.008 pp | USD8.33 +39.6% | 4 qtrs — |
| 12 | KENNEDY CAPITAL MANAGEMENT LLC | 658.1K -528.0 (-0.1%) | 7.65M -6.1K (-0.1%) | 0.87% -0.103 pp | 0.16% -0.007 pp | USD9.46 +22.9% | 6 qtrs — |
| 13 | MORGAN STANLEY | 648.8K -194.8K (-23.1%) | 7.55M -2.3M (-23.1%) | 0.85% -0.387 pp | 0.00% 0.000 pp | USD6.94 +67.6% | 28 qtrs — |
| 14 | UBS GROUP AG | 636.0K -454.9K (-41.7%) | 7.40M -5.3M (-41.7%) | 0.84% -0.768 pp | 0.00% -0.001 pp | USD10.49 +10.9% | 28 qtrs — |
| 15 | NORTHERN TRUST CORP | 614.6K -1.0K (-0.2%) | 7.15M -11.7K (-0.2%) | 0.81% -0.097 pp | 0.00% +0.000 pp | USD6.03 +92.9% | 28 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 610.9K +26.4K (+4.5%) | 7.11M +307.6K (+4.5%) | 0.80% -0.056 pp | 0.00% +0.000 pp | USD9.65 +20.5% | 27 qtrs — |
| 17 | PALISADES INVESTMENT PARTNERS, LLC | 576.8K +12.7K (+2.2%) | 6.71M +147.2K (+2.2%) | 0.76% -0.071 pp | 2.53% -0.042 pp | USD9.68 +20.1% | 5 qtrs — |
| 18 | RAYMOND JAMES FINANCIAL INC | 465.4K -186.5K (-28.6%) | 5.41M -2.2M (-28.6%) | 0.61% -0.347 pp | 0.00% -0.001 pp | USD11.11 +4.7% | 5 qtrs — |
| 19 | SQUAREPOINT OPS LLC | 432.2K +243.1K (+128.6%) | 5.03M +2.8M (+128.6%) | 0.57% +0.291 pp | 0.01% +0.003 pp | USD11.32 +2.7% | 4 qtrs — |
| 20 | PRIVATE ADVISOR GROUP, LLC | 378.5K +105.5K (+38.6%) | 4.40M +1.2M (+38.6%) | 0.50% +0.097 pp | 0.02% +0.005 pp | USD10.47 +11.1% | 28 qtrs — |
| 21 | BANK OF NEW YORK MELLON CORP | 376.9K +118.1K (+45.6%) | 4.38M +1.4M (+45.6%) | 0.50% +0.115 pp | 0.00% +0.000 pp | USD9.19 +26.6% | 28 qtrs — |
| 22 | NEW YORK STATE COMMON RETIREMENT FUND | 321.0K +23.5K (+7.9%) | 3.73M +273.7K (+7.9%) | 0.42% -0.015 pp | 0.01% +0.001 pp | USD10.12 +14.9% | 11 qtrs — |
| 23 | VICTORY CAPITAL MANAGEMENT INC | 315.0K +79.7K (+33.8%) | 3.66M +926.4K (+33.8%) | 0.41% +0.068 pp | 0.00% +0.001 pp | USD11.63 +0.0% | 2 qtrs — |
| 24 | OCTOBER EFFECT LTD | 306.4K -114.1K (-27.1%) | 3.56M -1.3M (-27.1%) | 0.40% -0.216 pp | 3.93% -1.465 pp | USD12.14 -4.2% | 3 qtrs — |
| 25 | ASSENAGON ASSET MANAGEMENT S.A. | 302.5K +78.4K (+35.0%) | 3.52M +912.3K (+35.0%) | 0.40% +0.069 pp | 0.00% +0.001 pp | USD11.63 +0.0% | 2 qtrs — |
| 26 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 288.9K -159.5K (-35.6%) | 3.36M -1.9M (-35.6%) | 0.38% -0.280 pp | 0.00% 0.000 pp | USD9.25 +25.7% | 27 qtrs — |
| 27 | AMERIPRISE FINANCIAL INC | 279.0K +42.6K (+18.0%) | 3.25M +495.6K (+18.0%) | 0.37% +0.019 pp | 0.00% +0.000 pp | USD9.61 +21.0% | 7 qtrs — |
| 28 | JANE STREET GROUP, LLC | 274.6K +63.0K (+29.7%) | 3.19M +732.2K (+29.7%) | 0.36% +0.050 pp | 0.00% +0.000 pp | USD12.16 -4.4% | 12 qtrs — |
| 29 | LAZARD ASSET MANAGEMENT LLC | 271.7K +271.7K (+100.0%) | 3.16M +3.2M (+100.0%) | 0.36% +0.358 pp | 0.01% +0.005 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 30 | ADVISOR GROUP HOLDINGS, INC. | 262.6K +215.6K (+458.2%) | 3.05M +2.5M (+433.7%) | 0.35% +0.277 pp | 0.00% +0.004 pp | USD11.50 +1.1% | 24 qtrs — |
| 31 | PACER ADVISORS, INC. | 253.9K +253.9K (+100.0%) | 2.95M +3.0M (+100.0%) | 0.33% +0.334 pp | 0.01% +0.008 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 32 | SWEDBANK AB | 250.0K +— (+0.0%) | 2.91M +— (+0.0%) | 0.33% -0.039 pp | 0.00% 0.000 pp | USD6.16 +88.8% | 4 qtrs — |
| 33 | ROYCE & ASSOCIATES LP | 242.0K -199.3K (-45.2%) | 2.81M -2.3M (-45.2%) | 0.32% -0.331 pp | 0.03% -0.023 pp | USD11.63 +0.0% | 2 qtrs — |
| 34 | LPL FINANCIAL LLC | 229.4K -91.3K (-28.5%) | 2.67M -1.1M (-28.5%) | 0.30% -0.170 pp | 0.00% 0.000 pp | USD10.40 +11.8% | 16 qtrs — |
| 35 | WELLINGTON MANAGEMENT GROUP LLP | 221.8K -28.6K (-11.4%) | 2.58M -332.7K (-11.4%) | 0.29% -0.077 pp | 0.00% 0.000 pp | USD8.25 +41.0% | 7 qtrs — |
| 36 | DEL-SETTE CAPITAL MANAGEMENT, LLC | 210.8K +210.8K (+100.0%) | 2.45M +2.5M (+100.0%) | 0.28% +0.278 pp | 1.51% +1.513 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 37 | HUSSMAN STRATEGIC ADVISORS, INC. | 210.0K -105.0K (-33.3%) | 2.44M -1.2M (-33.3%) | 0.28% -0.187 pp | 0.59% -0.203 pp | USD11.77 -1.2% | 3 qtrs — |
| 38 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 204.5K +14.6K (+7.7%) | 2.38M +169.9K (+7.7%) | 0.27% -0.010 pp | 0.01% +0.000 pp | USD8.39 +38.6% | 28 qtrs — |
| 39 | CITADEL ADVISORS LLC | 193.8K -129.0K (-40.0%) | 2.25M -1.5M (-40.0%) | 0.26% -0.220 pp | 0.00% 0.000 pp | USD6.95 +67.3% | 26 qtrs — |
| 40 | TWO SIGMA INVESTMENTS, LP | 181.1K +52.6K (+40.9%) | 2.11M +611.2K (+40.9%) | 0.24% +0.049 pp | 0.00% +0.001 pp | USD11.65 -0.2% | 23 qtrs — |
| 41 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 180.0K +180.0K (+100.0%) | 2.09M +2.1M (+100.0%) | 0.24% +0.237 pp | 0.01% +0.014 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 42 | NUVEEN, LLC | 174.0K -521.7K (-75.0%) | 2.02M -6.1M (-75.0%) | 0.23% -0.795 pp | 0.00% -0.002 pp | USD11.17 +4.1% | 4 qtrs — |
| 43 | PHOCAS FINANCIAL CORP. | 171.1K +171.1K (+100.0%) | 1.99M +2.0M (+100.0%) | 0.23% +0.225 pp | 0.26% +0.259 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 44 | DIADEMA PARTNERS LP | 159.0K +59.0K (+59.0%) | 1.85M +686.2K (+59.0%) | 0.21% +0.062 pp | 0.32% +0.021 pp | USD11.63 +0.0% | 2 qtrs — |
| 45 | MILLENNIUM MANAGEMENT LLC | 155.1K -240.4K (-60.8%) | 1.80M -2.8M (-60.8%) | 0.20% -0.378 pp | 0.00% -0.001 pp | USD10.85 +7.2% | 16 qtrs — |
| 46 | AQR CAPITAL MANAGEMENT LLC | 154.2K +78.5K (+103.8%) | 1.79M +913.4K (+103.8%) | 0.20% +0.092 pp | 0.00% +0.000 pp | USD11.66 -0.3% | 10 qtrs — |
| 47 | QUANTBOT TECHNOLOGIES LP | 147.8K +90.3K (+157.1%) | 1.72M +1.1M (+157.1%) | 0.19% +0.110 pp | 0.06% +0.039 pp | USD11.71 -0.7% | 3 qtrs — |
| 48 | SWISS NATIONAL BANK | 146.2K +— (+0.0%) | 1.70M +— (+0.0%) | 0.19% -0.023 pp | 0.00% +0.000 pp | USD7.23 +60.9% | 4 qtrs — |
| 49 | BARCLAYS PLC | 137.9K +60.1K (+77.1%) | 1.60M +974.9K (+155.0%) | 0.18% +0.067 pp | 0.00% +0.000 pp | USD9.54 +21.9% | 28 qtrs — |
| 50 | HENNION & WALSH ASSET MANAGEMENT, INC. | 137.9K +137.9K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.18% +0.182 pp | 0.06% +0.055 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 51 | JUMP FINANCIAL, LLC | 136.8K -637.3K (-82.3%) | 1.59M -7.4M (-82.3%) | 0.18% -0.959 pp | 0.02% -0.088 pp | USD11.63 +0.0% | 2 qtrs — |
| 52 | SANCTUARY ADVISORS, LLC | 134.7K +123.0K (+1,050.2%) | 1.57M +1.4M (+1,050.2%) | 0.18% +0.160 pp | 0.01% +0.008 pp | USD11.00 +5.7% | 7 qtrs — |
| 53 | EMPOWERED FUNDS, LLC | 131.9K +131.9K (+100.0%) | 1.53M +1.5M (+100.0%) | 0.17% +0.174 pp | 0.01% +0.012 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 54 | BANK OF AMERICA CORP /DE/ | 130.6K -154.1K (-54.1%) | 1.52M -1.8M (-54.1%) | 0.17% -0.247 pp | 0.00% 0.000 pp | USD11.24 +3.5% | 28 qtrs — |
| 55 | WINGATE WEALTH ADVISORS, INC. | 128.5K -1.0K (-0.8%) | 1.49M -12.0K (-0.8%) | 0.17% -0.022 pp | 0.83% -0.210 pp | USD8.21 +41.7% | 5 qtrs — |
| 56 | PRINCIPAL FINANCIAL GROUP INC | 126.7K +40.3K (+46.6%) | 1.47M +468.6K (+46.6%) | 0.17% +0.040 pp | 0.00% +0.000 pp | USD11.63 +0.0% | 2 qtrs — |
| 57 | AQUATIC CAPITAL MANAGEMENT LLC | 126.3K -21.8K (-14.7%) | 1.47M -253.2K (-14.7%) | 0.17% -0.052 pp | 0.04% +0.010 pp | USD11.63 +0.0% | 2 qtrs — |
| 58 | DIAMETRIC CAPITAL, LP | 125.0K +70.1K (+127.6%) | 1.45M +815.0K (+127.6%) | 0.16% +0.084 pp | 0.39% +0.153 pp | USD11.63 +0.0% | 4 qtrs — |
| 59 | FMR LLC | 123.8K +115.4K (+1,376.3%) | 1.44M +1.3M (+1,376.4%) | 0.16% +0.151 pp | 0.00% +0.000 pp | USD11.41 +1.9% | 16 qtrs — |
| 60 | MML INVESTORS SERVICES, LLC | 120.3K +27.8K (+30.0%) | 1.40M +322.7K (+30.0%) | 0.16% +0.022 pp | 0.00% +0.001 pp | USD11.63 +0.0% | 2 qtrs — |
| 61 | COMMONWEALTH EQUITY SERVICES, LLC | 113.5K -5.3K (-4.4%) | 1.32M -60.9K (-4.4%) | 0.15% -0.025 pp | 0.00% +0.000 pp | USD5.19 +124.1% | 8 qtrs — |
| 62 | UBS ASSET MANAGEMENT AMERICAS INC | 110.3K -6.5K (-5.6%) | 1.28M -76.0K (-5.6%) | 0.15% -0.027 pp | 0.00% +0.000 pp | USD8.89 +30.8% | 4 qtrs — |
| 63 | JPMORGAN CHASE & CO | 107.8K +10.5K (+10.8%) | 1.25M +122.6K (+10.8%) | 0.14% -0.001 pp | 0.00% +0.000 pp | USD10.35 +12.4% | 27 qtrs — |
| 64 | INSPIRE INVESTING, LLC | 107.3K +107.3K (+100.0%) | 1.25M +1.2M (+100.0%) | 0.14% +0.141 pp | 0.11% +0.112 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 65 | D. E. SHAW & CO., INC. | 106.4K +106.4K (+100.0%) | 1.24M +1.2M (+100.0%) | 0.14% +0.140 pp | 0.00% +0.001 pp | USD11.63 +0.0% | 16 qtrs — |
| 66 | CAMPBELL & CO INVESTMENT ADVISER LLC | 104.8K +66.6K (+174.2%) | 1.22M +774.6K (+174.2%) | 0.14% +0.082 pp | 0.06% +0.025 pp | USD11.18 +4.0% | 6 qtrs — |
| 67 | JANNEY MONTGOMERY SCOTT LLC | 103.3K +13.1K (+14.6%) | 1.20M +152.0K (+14.5%) | 0.14% +0.003 pp | 0.00% +0.000 pp | USD11.29 +3.0% | 5 qtrs — |
| 68 | ROUND ROCK ADVISORS, LLC | 92.0K +92.0K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.12% +0.121 pp | 0.16% +0.157 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 69 | WELLS FARGO & COMPANY/MN | 86.5K +39.6K (+84.5%) | 1.01M +460.7K (+84.5%) | 0.11% +0.045 pp | 0.00% +0.000 pp | USD9.45 +23.1% | 28 qtrs — |
| 70 | RHUMBLINE ADVISERS | 86.1K -9.5K (-9.9%) | 1.00M -110.2K (-9.9%) | 0.11% -0.027 pp | 0.00% 0.000 pp | USD5.56 +109.2% | 11 qtrs — |
| 71 | BALYASNY ASSET MANAGEMENT L.P. | 75.4K -83.6K (-52.6%) | 877.4K -972.1K (-52.6%) | 0.10% -0.135 pp | 0.00% -0.001 pp | USD11.88 -2.1% | 7 qtrs — |
| 72 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 71.3K +14.6K (+25.8%) | 829.3K +170.1K (+25.8%) | 0.09% +0.011 pp | 0.00% +0.000 pp | USD7.17 +62.2% | 11 qtrs — |
| 73 | ALLWORTH FINANCIAL LP | 69.7K +8.8K (+14.4%) | 810.7K +101.9K (+14.4%) | 0.09% +0.002 pp | 0.00% +0.000 pp | USD11.69 -0.5% | 9 qtrs — |
| 74 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 67.8K -78.7K (-53.7%) | 788.9K -914.8K (-53.7%) | 0.09% -0.126 pp | 0.01% +0.001 pp | USD11.72 -0.8% | 3 qtrs — |
| 75 | WEST MICHIGAN ADVISORS, LLC | 66.0K +33.0K (+100.0%) | 767.6K +383.8K (+100.0%) | 0.09% +0.038 pp | 0.18% +0.084 pp | USD11.63 +0.0% | 2 qtrs — |
| 76 | LEGAL & GENERAL GROUP PLC | 65.8K -152.0 (-0.2%) | 765.0K -2.0K (-0.3%) | 0.09% -0.010 pp | 0.00% +0.000 pp | USD7.10 +63.8% | 11 qtrs — |
| 77 | ALLIANCEBERNSTEIN L.P. | 61.8K +— (+0.0%) | 718.5K +— (+0.0%) | 0.08% -0.010 pp | 0.00% +0.000 pp | USD7.39 +57.4% | 10 qtrs — |
| 78 | LOS ANGELES CAPITAL MANAGEMENT LLC | 61.6K +23.8K (+62.9%) | 715.3K +275.7K (+62.7%) | 0.08% +0.025 pp | 0.00% +0.001 pp | USD11.63 +0.0% | 2 qtrs — |
| 79 | SEGALL BRYANT & HAMILL, LLC | 61.0K +61.0K (+100.0%) | 708.9K +708.9K (+100.0%) | 0.08% +0.080 pp | 0.01% +0.010 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 80 | CETERA INVESTMENT ADVISERS | 56.3K +17.5K (+45.2%) | 655.1K +203.8K (+45.2%) | 0.07% +0.017 pp | 0.00% +0.000 pp | USD10.15 +14.6% | 8 qtrs — |
| 81 | SEI INVESTMENTS CO | 56.3K +34.7K (+160.7%) | 654.6K +403.5K (+160.7%) | 0.07% +0.042 pp | 0.00% +0.000 pp | USD11.89 -2.2% | 3 qtrs — |
| 82 | CAXTON ASSOCIATES LLP | 53.3K +53.3K (+100.0%) | 620.0K +620.0K (+100.0%) | 0.07% +0.070 pp | 0.01% +0.012 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 83 | VERSOR INVESTMENTS LP | 51.4K +51.4K (+100.0%) | 597.8K +597.8K (+100.0%) | 0.07% +0.068 pp | 0.09% +0.093 pp | USD11.63 +0.0% | 1 qtrs NEW |
| 84 | AMERICAN FINANCIAL ADVISORS, LLC | 50.1K +5.0K (+11.1%) | 582.2K +58.2K (+11.1%) | 0.07% 0.000 pp | 0.08% +0.008 pp | USD6.72 +73.1% | 11 qtrs — |
| 85 | INVESCO LTD. | 49.5K -407.4K (-89.2%) | 575.8K -4.7M (-89.2%) | 0.07% -0.607 pp | 0.00% -0.001 pp | USD9.46 +22.9% | 11 qtrs — |
| 86 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 49.4K +44.7K (+951.5%) | 573.0K +519.0K (+961.1%) | 0.07% +0.058 pp | 0.01% +0.006 pp | USD11.63 +0.0% | 2 qtrs — |
| 87 | CITIGROUP INC | 48.8K +114.0 (+0.2%) | 568.1K +1.3K (+0.2%) | 0.06% -0.007 pp | 0.00% +0.000 pp | USD8.62 +34.9% | 11 qtrs — |
| 88 | LIDO ADVISORS, LLC | 46.7K +— (+0.0%) | 543.4K +— (+0.0%) | 0.06% -0.007 pp | 0.00% 0.000 pp | USD5.66 +105.5% | 11 qtrs — |
| 89 | AVIVA PLC | 46.1K +8.0K (+21.1%) | 535.7K +93.4K (+21.1%) | 0.06% +0.005 pp | 0.00% +0.000 pp | USD11.63 +0.0% | 2 qtrs — |
| 90 | DEUTSCHE BANK AG\ | 46.1K +2.3K (+5.2%) | 535.7K +26.6K (+5.2%) | 0.06% -0.004 pp | 0.00% +0.000 pp | USD8.76 +32.8% | 11 qtrs — |
| 91 | CANADA PENSION PLAN INVESTMENT BOARD | 45.4K +32.8K (+260.3%) | 528.0K +381.5K (+260.3%) | 0.06% +0.041 pp | 0.00% +0.000 pp | USD11.68 -0.4% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 88 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.06% | 4.98M | 0.35% |
| 2 | First Trust Active Factor Small Cap ETF AFSM | 0.35% | 399.5K | 0.75% |
| 3 | VictoryShares Small Cap Free Cash Flow ETF SFLO | 0.27% | 1.71M | 0.56% |
| 4 | Royce Quant Small-Cap Quality Value ETF SQLV | 0.25% | 72.7K | 0.60% |
| 5 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.22% | 51.2K | 1.22% |
| 6 | Pacer US Small Cap Cash Cows ETF CALF | 0.15% | 5.33M | 0.59% |
| 7 | iShares Micro-Cap ETF IWC | 0.14% | 2.11M | 0.60% |
| 8 | WisdomTree U.S. SmallCap Fund EES | 0.14% | 1.02M | 0.38% |
| 9 | iShares U.S. Pharmaceuticals ETF IHE | 0.14% | 1.85M | 0.38% |
| 10 | American Century Small Cap Growth Insights ETF ACSG | 0.11% | 28.8K | 0.49% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.08
Neutral
Ratio by volume
3.00
Bullish
Buys
13
Sells
12
Shares acquired
825.0K
Shares disposed
179.3K
Cash buys
—
Cash sales
1.00
Net activity
+645,666
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | Zelnick Kaufman Beth | Officer | A-Award | A | Common Stock | 36,006 | 0.00 | — | 269,108 | D | ↗ |
| 2026-02-04 | Todisco Joseph | Director / Officer | A-Award | A | Common Stock | 77,156 | 0.00 | — | 774,749 | D | ↗ |
| 2026-02-04 | Hurlburt Elizabeth | Officer | A-Award | A | Common Stock | 36,006 | 0.00 | — | 278,539 | D | ↗ |
| 2026-01-26 | Stewart Robert A | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 66,453 | D | ↗ |
| 2026-01-26 | Lefkowitz Steven W | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 125,951 | D | ↗ |
| 2026-01-26 | Kaplan Myron | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 231,487 | D | ↗ |
| 2026-01-26 | Duncan Gregory Scott | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 68,786 | D | ↗ |
| 2026-01-26 | Dillione Janet | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 68,926 | D | ↗ |
| 2026-01-26 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 30,453 | 0.00 | — | 70,703 | D | ↗ |
| 2026-01-23 | Zelnick Kaufman Beth | Officer | F-InKind | D | Common Stock | 8,803 | 7.27 | 64.0K | 233,102 | D | ↗ |
| 2026-01-23 | Todisco Joseph | Director / Officer | A-Award | A | Common Stock | 225,900 | 0.00 | — | 724,899 | D | ↗ |
| 2026-01-23 | Hurlburt Elizabeth | Officer | F-InKind | D | Common Stock | 10,778 | 7.27 | 78.4K | 242,533 | D | ↗ |
| 2026-01-23 | Blum Susan | Officer | F-InKind | D | Common Stock | 9,767 | 7.27 | 71.0K | 132,739 | D | ↗ |
| 2026-01-21 | Dillione Janet | Director | S-Sale | D | Common Stock | 10,000 | 6.88 | 68.8K | 38,473 | D | ↗ |
| 2026-01-17 | Todisco Joseph | Director / Officer | F-InKind | D | Common Stock | 22,665 | 6.78 | 153.7K | 498,999 | D | ↗ |
| 2026-01-16 | Todisco Joseph | Director / Officer | M-Exempt | D | Stock Option (Right to Buy Common Stock) | 29,585 | 3.38 | 100.0K | 411,245 | D | ↗ |
| 2026-01-12 | Todisco Joseph | Director / Officer | F-InKind | D | Common Stock | 17,417 | 7.15 | 124.5K | 492,079 | D | ↗ |
| 2026-01-12 | Lefkowitz Steven W | Director | M-Exempt | D | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 0 | D | ↗ |
| 2026-01-12 | Hurlburt Elizabeth | Officer | F-InKind | D | Common Stock | 5,794 | 7.15 | 41.4K | 160,301 | D | ↗ |
| 2026-01-08 | Seckler Michael David | Officer | A-Award | A | Common Stock | 133,156 | 0.00 | — | 133,156 | D | ↗ |
| 2026-01-02 | Zelnick Kaufman Beth | Officer | F-InKind | D | Common Stock | 11,333 | 12.16 | 137.8K | 169,085 | D | ↗ |
| 2026-01-02 | Hurlburt Elizabeth | Officer | F-InKind | D | Common Stock | 10,895 | 12.16 | 132.5K | 166,095 | D | ↗ |
| 2025-12-30 | DUNTON ALAN W | Director | M-Exempt | A | Common Stock | 20,000 | 4.03 | 80.6K | 60,250 | D | ↗ |
| 2025-12-18 | Todisco Joseph | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 4.43 | 132.9K | 539,496 | D | ↗ |
| 2025-12-09 | Lefkowitz Steven W | Director | S-Sale | D | Common Stock | 40,000 | 11.88 | 475.2K | 80,498 | D | ↗ |
| 2025-12-09 | Dillione Janet | Director | M-Exempt | D | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 0 | D | ↗ |
| 2025-12-02 | Dillione Janet | Director | M-Exempt | A | Common Stock | 19,323 | 3.55 | 68.6K | 95,130 | D | ↗ |
| 2025-11-24 | Dillione Janet | Director | S-Sale | D | Common Stock | 26,343 | 9.93 | 261.6K | 48,473 | D | ↗ |
| 2025-11-14 | Dillione Janet | Director | S-Sale | D | Common Stock | 30,000 | 11.42 | 342.6K | 48,473 | D | ↗ |
| 2025-10-23 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 25,000 | 11.02 | 275.5K | 201,034 | D | ↗ |
| 2025-09-16 | Duncan Gregory Scott | Director | M-Exempt | A | Common Stock | 13,333 | 8.32 | 110.9K | 38,333 | D | ↗ |
| 2025-09-12 | Todisco Joseph | Officer | M-Exempt | A | Common Stock | 50,000 | 3.47 | 173.5K | 559,496 | D | ↗ |
| 2025-09-12 | DUNTON ALAN W | Director | M-Exempt | A | Common Stock | 10,000 | 3.55 | 35.5K | 50,250 | D | ↗ |
| 2025-09-11 | Hurlburt Elizabeth | Officer | M-Exempt | A | Common Stock | 41,121 | 1.45 | 59.6K | 218,111 | D | ↗ |
| 2025-09-09 | Zelnick Kaufman Beth | Officer | M-Exempt | D | Stock Option (Right to Buy Common Stock) | 50,000 | 3.30 | 165.0K | 150,000 | D | ↗ |
| 2025-09-09 | Hurlburt Elizabeth | Officer | S-Sale | D | Common Stock | 12,876 | 13.51 | 174.0K | 176,990 | D | ↗ |
| 2025-08-29 | Zelnick Kaufman Beth | Officer | F-InKind | D | Common Stock | 8,880 | 14.83 | 131.7K | 180,418 | D | ↗ |
| 2025-08-29 | Hurlburt Elizabeth | Officer | F-InKind | D | Common Stock | 8,424 | 14.83 | 124.9K | 176,990 | D | ↗ |
| 2025-08-29 | Blum Susan | Officer | A-Award | A | Common Stock | 69,686 | 0.00 | — | 69,686 | D | ↗ |
| 2025-05-10 | Todisco Joseph | Officer | F-InKind | D | Common Stock | 21,225 | 11.66 | 247.5K | 509,496 | D | ↗ |
| 2025-04-02 | Lefkowitz Steven W | Director | M-Exempt | D | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 0 | D | ↗ |
| 2025-04-01 | Todisco Joseph | Director / Officer | M-Exempt | A | Common Stock | 59,170 | 3.38 | 200.0K | 530,721 | D | ↗ |
| 2025-01-17 | Todisco Joseph | Director / Officer | A-Award | A | Common Stock | 187,500 | 0.00 | — | 495,528 | D | ↗ |
| 2025-01-17 | Stewart Robert A | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 36,000 | D | ↗ |
| 2025-01-17 | Lefkowitz Steven W | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 100,498 | D | ↗ |
| 2025-01-17 | Kaplan Myron | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 176,034 | D | ↗ |
| 2025-01-17 | Duncan Gregory Scott | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-01-17 | Dillione Janet | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 78,473 | D | ↗ |
| 2025-01-17 | DUNTON ALAN W | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 40,250 | D | ↗ |
| 2025-01-10 | Todisco Joseph | Director / Officer | F-InKind | D | Common Stock | 17,829 | 11.19 | 199.5K | 308,028 | D | ↗ |
| 2025-01-10 | Mistry Erin | Officer | F-InKind | D | Common Stock | 5,689 | 11.19 | 63.7K | 100,992 | D | ↗ |
| 2025-01-10 | Hurlburt Elizabeth | Officer | F-InKind | D | Common Stock | 5,790 | 11.19 | 64.8K | 115,728 | D | ↗ |
| 2025-01-10 | David Matthew T | Officer | F-InKind | D | Common Stock | 6,515 | 11.19 | 72.9K | 95,270 | D | ↗ |
| 2025-01-02 | Zelnick Kaufman Beth | Officer | F-InKind | D | Common Stock | 11,844 | 8.22 | 97.4K | 119,612 | D | ↗ |
| 2025-01-02 | Mistry Erin | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 114,511 | D | ↗ |
| 2025-01-02 | Hurlburt Elizabeth | Officer | A-Award | A | Common Stock | 87,500 | 0.00 | — | 132,897 | D | ↗ |
| 2025-01-02 | David Matthew T | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 110,434 | D | ↗ |
| 2024-12-12 | Zelnick Kaufman Beth | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 62,500 | D | ↗ |
| 2024-11-14 | Hurlburt Elizabeth | Officer | M-Exempt | A | Common Stock | 9,888 | 5.63 | 55.7K | 63,457 | D | ↗ |
| 2024-10-31 | Mistry Erin | Officer | P-Purchase | A | Common Stock | 1,500 | 9.99 | 15.0K | 52,011 | D | ↗ |
| 2024-05-10 | Todisco Joseph | Director / Officer | F-InKind | D | Common Stock | 26,982 | 5.17 | 139.5K | 325,857 | — | ↗ |
| 2024-03-13 | Todisco Joseph | Director / Officer | P-Purchase | A | Common Stock | 13,561 | 3.74 | 50.7K | 352,839 | — | ↗ |
| 2024-03-05 | Stewart Robert A | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-03-05 | Lefkowitz Steven W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-03-05 | Kaplan Myron | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-03-05 | Duncan Gregory Scott | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-03-05 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-03-05 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 3.55 | 106.5K | 30,000 | — | ↗ |
| 2024-01-12 | Todisco Joseph | Director / Officer | A-Award | A | Common Stock | 133,333 | 0.00 | — | 353,059 | — | ↗ |
| 2024-01-12 | Mistry Erin | Officer | F-InKind | D | Common Stock | 4,389 | 3.47 | 15.2K | 50,511 | — | ↗ |
| 2024-01-12 | Masson-Hurlburt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 100,000 | 3.47 | 347.0K | 100,000 | — | ↗ |
| 2024-01-12 | David Matthew T | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 53,150 | — | ↗ |
| 2023-12-15 | DUNTON ALAN W | Director | P-Purchase | A | Common Stock | 3,000 | 3.30 | 9.9K | 15,250 | — | ↗ |
| 2023-12-14 | DUNTON ALAN W | Director | P-Purchase | A | Common Stock | 3,000 | 3.45 | 10.4K | 12,250 | — | ↗ |
| 2023-12-12 | Zelnick Kaufman Beth | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-17 | Mistry Erin | Officer | P-Purchase | A | Common Stock | 1,000 | 4.00 | 4.0K | 4,900 | — | ↗ |
| 2023-11-16 | Lefkowitz Steven W | Director | M-Exempt | A | Common Stock | 15,000 | 2.25 | 33.8K | 75,498 | — | ↗ |
| 2023-09-08 | Todisco Joseph | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 3.71 | 37.1K | 219,726 | — | ↗ |
| 2023-05-18 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 6,000 | 4.54 | 27.3K | 166,034 | — | ↗ |
| 2023-05-17 | Todisco Joseph | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.58 | 22.9K | 209,726 | — | ↗ |
| 2023-05-17 | Stewart Robert A | Director | A-Award | A | Common Stock | 10,000 | 4.37 | 43.7K | 11,000 | — | ↗ |
| 2023-05-17 | DUNTON ALAN W | Director | P-Purchase | A | Common Stock | 3,000 | 4.33 | 13.0K | 9,250 | — | ↗ |
| 2023-05-17 | Costa Paulo F | Director | P-Purchase | A | Common Stock | 10,000 | 4.65 | 46.5K | 10,000 | — | ↗ |
| 2023-05-10 | Todisco Joseph | Director / Officer | F-InKind | D | Common Stock | 37,443 | 5.30 | 198.4K | 204,726 | — | ↗ |
| 2023-04-13 | Stewart Robert A | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 14,200 | 5.25 | 74.6K | 14,200 | — | ↗ |
| 2023-01-15 | Mistry Erin | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,900 | — | ↗ |
| 2023-01-14 | Todisco Joseph | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2023-01-14 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2023-01-14 | Mistry Erin | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-01-14 | Masson-Hurlburt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2023-01-14 | Lefkowitz Steven W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-14 | Kaplan Myron | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-14 | Duncan Gregory Scott | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-14 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-14 | David Matthew T | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2023-01-14 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-14 | Costa Paulo F | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-11-15 | Todisco Joseph | Officer | P-Purchase | A | Common Stock | 20,000 | 3.82 | 76.4K | 242,169 | — | ↗ |
| 2022-08-24 | Todisco Joseph | Director / Officer | P-Purchase | A | Common Stock | 4,700 | 3.92 | 18.4K | 222,169 | — | ↗ |
| 2022-05-17 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 5,000 | 3.78 | 18.9K | 160,034 | — | ↗ |
| 2022-05-16 | Todisco Joseph | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 3.38 | 33.8K | 217,469 | — | ↗ |
| 2022-05-10 | Todisco Joseph | Director / Officer | A-Award | A | Common Stock | 207,469 | 0.00 | — | 207,469 | — | ↗ |
| 2022-03-18 | Todisco Joseph | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-22 | Lefkowitz Steven W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-22 | Kaplan Myron | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-22 | Duncan Gregory Scott | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-22 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-22 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-22 | Costa Paulo F | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 4.03 | 80.6K | 20,000 | — | ↗ |
| 2022-02-18 | Nusbickel Thomas | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 100,000 | 4.03 | 403.0K | 100,000 | — | ↗ |
| 2022-02-18 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 4.03 | 564.2K | 140,000 | — | ↗ |
| 2022-02-18 | Masson-Hurlburt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 100,000 | 4.03 | 403.0K | 100,000 | — | ↗ |
| 2022-02-18 | David Matthew T | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 0 | 4.03 | — | 100,000 | — | ↗ |
| 2021-12-27 | Kaplan Myron | Director | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 140,034 | — | ↗ |
| 2021-12-06 | David Matthew T | Officer | P-Purchase | A | Common Stock | 1,000 | 4.50 | 4.5K | 3,150 | — | ↗ |
| 2021-11-17 | David Matthew T | Officer | P-Purchase | A | Common Stock | 1,000 | 5.07 | 5.1K | 2,150 | — | ↗ |
| 2021-11-16 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 10,000 | 5.14 | 51.4K | 175,034 | — | ↗ |
| 2021-11-01 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 0 | 5.56 | — | 100,000 | — | ↗ |
| 2021-11-01 | David Matthew T | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 125,000 | 5.56 | 695.0K | 125,000 | — | ↗ |
| 2021-05-21 | Masson-Hurlburt Elizabeth | Officer | S-Sale | D | Common Stock | 8,000 | 6.92 | 55.4K | 0 | — | ↗ |
| 2021-05-17 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 15,000 | 6.03 | 90.5K | 165,034 | — | ↗ |
| 2021-05-13 | Nusbickel Thomas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-11 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 140,000 | 8.32 | 1.16M | 140,000 | — | ↗ |
| 2021-01-11 | Masson-Hurlburt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 140,000 | 8.32 | 1.16M | 140,000 | — | ↗ |
| 2021-01-11 | Lefkowitz Steven W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 8.32 | 249.6K | 30,000 | — | ↗ |
| 2021-01-11 | Kaplan Myron | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 8.32 | 249.6K | 30,000 | — | ↗ |
| 2021-01-11 | Duncan Gregory Scott | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 8.32 | 166.4K | 20,000 | — | ↗ |
| 2021-01-11 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 8.32 | 249.6K | 30,000 | — | ↗ |
| 2021-01-11 | David Matthew T | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 80,000 | 8.32 | 665.6K | 80,000 | — | ↗ |
| 2021-01-11 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 30,000 | 8.32 | 249.6K | 30,000 | — | ↗ |
| 2021-01-11 | Costa Paulo F | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 8.32 | 166.4K | 20,000 | — | ↗ |
| 2021-01-11 | Baluch Khoso | Director / Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 320,000 | 8.32 | 2.66M | 320,000 | — | ↗ |
| 2021-01-11 | ARMSTRONG JR. JOHN L. | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 140,000 | 8.32 | 1.16M | 140,000 | — | ↗ |
| 2020-11-16 | Dillione Janet | Director | A-Award | A | Phantom Stock | 3,583 | 0.00 | — | 3,583 | — | ↗ |
| 2020-11-02 | Duncan Gregory Scott | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 5.00 | 100.0K | 20,000 | — | ↗ |
| 2020-09-15 | Costa Paulo F | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 3,750 | 4.57 | 17.1K | 3,750 | — | ↗ |
| 2020-09-04 | Lefkowitz Steven W | Director | P-Purchase | A | Common Stock | 2,215 | 3.98 | 8.8K | 60,498 | — | ↗ |
| 2020-09-03 | David Matthew T | Officer | P-Purchase | A | Common Stock | 1,150 | 4.07 | 4.7K | 1,150 | — | ↗ |
| 2020-09-02 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 15,300 | 4.27 | 65.4K | 150,034 | — | ↗ |
| 2020-08-19 | Khan Mehmood | Director | P-Purchase | A | Common Stock | 8,433 | 4.90 | 41.3K | 178,767 | — | ↗ |
| 2020-08-18 | Khan Mehmood | Director | P-Purchase | A | Common Stock | 21,082 | 4.86 | 102.4K | 160,930 | — | ↗ |
| 2020-08-14 | Dillione Janet | Director | A-Award | A | Phantom Stock | 4,770 | 0.00 | — | 4,770 | — | ↗ |
| 2020-08-14 | ARMSTRONG JR. JOHN L. | Officer | P-Purchase | A | Common Stock | 10,000 | 4.35 | 43.5K | 96,878 | — | ↗ |
| 2020-08-13 | Mounts Phoebe | Officer | P-Purchase | A | Common Stock | 2,525 | 4.03 | 10.2K | 7,200 | — | ↗ |
| 2020-08-13 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 15,000 | 4.08 | 61.2K | 134,734 | — | ↗ |
| 2020-08-13 | Baluch Khoso | Director / Officer | P-Purchase | A | Common Stock | 4,830 | 4.14 | 20.0K | 60,905 | — | ↗ |
| 2020-08-12 | DUNTON ALAN W | Director | P-Purchase | A | Common Stock | 5,000 | 3.95 | 19.8K | 6,250 | — | ↗ |
| 2020-05-15 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 10,000 | 3.85 | 38.5K | 119,734 | — | ↗ |
| 2020-05-15 | Dillione Janet | Director | A-Award | A | Phantom Stock | 5,253 | 0.00 | — | 5,253 | — | ↗ |
| 2020-05-11 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 50,000 | 5.63 | 281.5K | 50,000 | — | ↗ |
| 2020-05-11 | Masson-Hurlburt Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 37,500 | 4.08 | 153.0K | 37,500 | — | ↗ |
| 2020-05-11 | David Matthew T | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 125,000 | 4.08 | 510.0K | 125,000 | — | ↗ |
| 2020-05-11 | ARMSTRONG JR. JOHN L. | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 37,500 | 4.08 | 153.0K | 37,500 | — | ↗ |
| 2020-03-18 | Mounts Phoebe | Officer | P-Purchase | A | Common Stock | 3,250 | 3.05 | 9.9K | 4,675 | — | ↗ |
| 2020-03-18 | Baluch Khoso | Director / Officer | P-Purchase | A | Common Stock | 3,500 | 2.61 | 9.1K | 56,075 | — | ↗ |
| 2020-02-25 | Mounts Phoebe | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 24,764 | 5.63 | 139.4K | 24,764 | — | ↗ |
| 2020-02-25 | Masson Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 24,764 | 5.63 | 139.4K | 24,764 | — | ↗ |
| 2020-02-25 | Lefkowitz Steven W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 15,000 | — | ↗ |
| 2020-02-25 | Khan Mehmood | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 15,000 | — | ↗ |
| 2020-02-25 | Kaplan Myron | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 15,000 | — | ↗ |
| 2020-02-25 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 15,000 | — | ↗ |
| 2020-02-25 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 15,000 | 5.63 | 84.5K | 15,000 | — | ↗ |
| 2020-02-25 | Baluch Khoso | Director / Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 100,630 | 5.63 | 566.5K | 100,630 | — | ↗ |
| 2020-02-25 | ARMSTRONG JR. JOHN L. | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 24,764 | 5.63 | 139.4K | 24,764 | — | ↗ |
| 2020-02-14 | Dillione Janet | Director | A-Award | A | Phantom Stock | 1,706 | 0.00 | — | 1,706 | — | ↗ |
| 2020-01-07 | Lefkowitz Steven W | Director | X-InTheMoney | A | Warrant (Right to Purchase Common Stock) | 3,000 | 4.50 | 13.5K | 3,000 | — | ↗ |
| 2019-12-30 | Mounts Phoebe | Officer | P-Purchase | A | Common Stock | 1,425 | 7.04 | 10.0K | 1,425 | — | ↗ |
| 2019-12-13 | Khan Mehmood | Director | P-Purchase | A | Common Stock | 17,000 | 6.58 | 111.9K | 133,017 | — | ↗ |
| 2019-11-14 | Dillione Janet | Director | A-Award | A | Phantom Stock | 2,099 | 0.00 | — | 2,099 | — | ↗ |
| 2019-09-30 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 5,000 | 6.81 | 34.1K | 109,734 | — | ↗ |
| 2019-09-30 | Cook Robert W. | Officer | P-Purchase | A | Common Stock | 1,000 | 6.88 | 6.9K | 27,517 | — | ↗ |
| 2019-09-27 | Lefkowitz Steven W | Director | P-Purchase | A | Common Stock | 5,000 | 6.75 | 33.8K | 55,276 | — | ↗ |
| 2019-09-26 | Baluch Khoso | Director / Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 120,000 | 6.82 | 818.4K | 120,000 | — | ↗ |
| 2019-08-16 | Kaplan Myron | Director | P-Purchase | A | Common Stock | 6,000 | 8.06 | 48.4K | 104,734 | — | ↗ |
| 2019-08-16 | Dillione Janet | Director | P-Purchase | A | Common Stock | 6,147 | 8.19 | 50.3K | 53,473 | — | ↗ |
| 2019-08-16 | Cook Robert W. | Officer | P-Purchase | A | Common Stock | 1,000 | 8.18 | 8.2K | 26,517 | — | ↗ |
| 2019-08-14 | Dillione Janet | Director | A-Award | A | Phantom Stock | 945 | 0.00 | — | 945 | — | ↗ |
| 2019-07-12 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 7,500 | 8.95 | 67.1K | 7,500 | — | ↗ |
| 2019-05-15 | Dillione Janet | Director | A-Award | A | Phantom Stock | 1,126 | 0.00 | — | 226 | — | ↗ |
| 2019-05-01 | Mounts Phoebe | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-29 | Cook Robert W. | Officer | P-Purchase | A | Common Stock | 100 | 9.35 | 935.00 | 25,517 | — | ↗ |
| 2019-03-26 | Baluch Khoso | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 7.55 | 18.9K | 52,575 | — | ↗ |
| 2019-03-26 | ARMSTRONG JR. JOHN L. | Officer | P-Purchase | A | Common Stock | 5,000 | 7.73 | 38.7K | 69,378 | — | ↗ |
| 2019-03-25 | ARMSTRONG JR. JOHN L. | Officer | P-Purchase | A | Common Stock | 15,000 | 1.69 | 25.4K | 321,890 | — | ↗ |
| 2019-03-22 | Kaplan Myron | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-18 | Dillione Janet | Director | P-Purchase | A | Common Stock | 42,000 | 1.67 | 70.0K | 180,909 | — | ↗ |
| 2019-03-01 | DUNTON ALAN W | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 20,000 | 8.50 | 170.0K | 20,000 | — | ↗ |
| 2019-02-14 | Dillione Janet | Director | A-Award | A | Phantom Stock | 4,213 | 0.00 | — | 4,213 | — | ↗ |
| 2019-01-10 | Masson Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 120,000 | 1.66 | 199.2K | 120,000 | — | ↗ |
| 2019-01-10 | Lefkowitz Steven W | Director | A-Award | A | Restricted Stock Units | 12,500 | 0.00 | — | 233,879 | — | ↗ |
| 2019-01-10 | Khan Mehmood | Director | A-Award | A | Restricted Stock Units | 12,500 | 0.00 | — | 577,083 | — | ↗ |
| 2019-01-10 | Kaplan Myron | Director | A-Award | A | Restricted Stock Units | 5,000 | 0.00 | — | 473,666 | — | ↗ |
| 2019-01-10 | Gelbfish Gary A. | Director | A-Award | A | Restricted Stock Units | 12,500 | 0.00 | — | 2,654,871 | — | ↗ |
| 2019-01-10 | Dillione Janet | Director | A-Award | A | Stock Option (Right to Buy Common Stock) | 75,000 | 1.66 | 124.5K | 75,000 | — | ↗ |
| 2019-01-10 | Cook Robert W. | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 100,000 | 1.66 | 166.0K | 100,000 | — | ↗ |
| 2019-01-10 | Baluch Khoso | Director / Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 400,000 | 1.66 | 664.0K | 400,000 | — | ↗ |
| 2019-01-10 | ARMSTRONG JR. JOHN L. | Officer | A-Award | A | Stock Option (Right to Buy Common Stock) | 45,000 | 1.66 | 74.7K | 45,000 | — | ↗ |
| 2018-12-31 | ARMSTRONG JR. JOHN L. | Officer | M-Exempt | D | Restricted Stock Units | 18,029 | 0.00 | — | 0 | — | ↗ |
| 2018-12-20 | Lefkowitz Steven W | Director | P-Purchase | A | Common Stock, $0.001 par value per share | 20,000 | 1.18 | 23.5K | 135,757 | — | ↗ |
| 2018-12-20 | Khan Mehmood | Director | P-Purchase | A | Common Stock | 100,000 | 1.24 | 124.4K | 564,583 | — | ↗ |
Executive team
Top executives
EBIT / Employee
2.35M
Shares Outstanding
78.44M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joseph Todisco Chief Executive Officer | 684.4K | — | 4.49M | — | 865.1K | 59.3K | 6.10M | 73.63% | ↗ |
| 2 | 2025 | Beth Zelnick Kaufman Executive Vice President, Chief Legal/Compliance Officer & Corp. Secretary | 497.6K | — | 2.78M | — | 435.9K | 48.1K | 3.77M | 73.93% | ↗ |
| 3 | 2025 | Elizabeth Hurlburt Executive Vice President, Chief Operating Officer | 479.6K | — | 2.78M | — | 420.5K | 59.2K | 3.74M | 74.37% | ↗ |
| 4 | 2024 | Joseph Todisco Chief Executive Officer | 639.2K | — | 462.7K | 745.8K | 457.3K | 54.9K | 2.36M | 51.21% | ↗ |
| 5 | 2024 | Elizabeth Hurlburt Executive Vice President, Chief Clinical Strategy and Operations Officer | 405.9K | — | 173.5K | 279.7K | 223.3K | 53.0K | 1.14M | 39.91% | ↗ |
| 6 | 2024 | Elizabeth Hurlburt Executive Vice President, Chief Operating Officer | 405.9K | — | 173.5K | 279.7K | 223.3K | 53.0K | 1.14M | 39.91% | ↗ |
| 7 | 2024 | Matthew David Chief Financial Officer | 409.1K | — | 173.5K | 279.7K | 171.2K | 54.6K | 1.09M | 41.65% | ↗ |
| 8 | 2024 | Beth Zelnick Kaufman Executive Vice President, Chief Legal/Compliance Officer & Corp. Secretary | 450.0K | — | — | — | 217.8K | 46.6K | 714.4K | 0.00% | ↗ |
| 9 | 2023 | Joseph Todisco Chief Executive Officer | 617.0K | — | — | 1.39M | 401.7K | 52.4K | 2.46M | 56.45% | ↗ |
| 10 | 2023 | Phoebe Mounts Former Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375.0K | — | — | 433.9K | 112.5K | 333.2K | 1.25M | 34.58% | ↗ |
| 11 | 2023 | Erin Mistry Executive Vice President and Chief Commercial Officer | 389.6K | — | — | 694.2K | 156.8K | — | 1.24M | 55.96% | ↗ |
| 12 | 2023 | Matthew David Chief Financial Officer | 389.1K | — | — | 433.9K | 156.0K | 52.1K | 1.03M | 42.08% | ↗ |
| 13 | 2022 | Joseph Todisco Chief Executive Officer | 378.5K | — | 701.2K | 1.27M | 305.8K | 32.2K | 2.69M | 73.38% | ↗ |
| 14 | 2022 | Matthew David Chief Financial Officer | 393.5K | — | — | 305.9K | 389.5K | 47.7K | 1.14M | 26.91% | ↗ |
| 15 | 2022 | Matthew David Executive Vice President and Chief Financial Officer | 393.5K | — | — | 305.9K | 389.5K | 47.7K | 1.14M | 26.91% | ↗ |
| 16 | 2022 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375.0K | — | — | 428.3K | 195.1K | 12.1K | 1.01M | 42.38% | ↗ |
| 17 | 2022 | Phoebe Mounts Former Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375.0K | — | — | 428.3K | 195.1K | 12.1K | 1.01M | 42.38% | ↗ |
| 18 | 2022 | Thomas Nusbickel Former Chief Commercial Officer | 191.8K | — | — | 305.9K | 31.4K | 416.8K | 945.9K | 32.34% | ↗ |
| 19 | 2022 | Elizabeth Hurlburt Executive Vice President and Head of Clinical Operations | 346.3K | — | — | 305.9K | 175.6K | 16.9K | 844.8K | 36.21% | ↗ |
| 20 | 2021 | Khoso Baluch Former Chief Executive Officer | 366.7K | — | — | 1.70M | — | 531.4K | 2.60M | 65.41% | ↗ |
| 21 | 2021 | Thomas Nusbickel Former Chief Commercial Officer | 233.7K | 75.0K | — | 1.54M | — | 27.7K | 1.88M | 82.08% | ↗ |
| 22 | 2021 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations | 375.0K | 61.9K | — | 1.16M | — | 11.4K | 1.61M | 72.21% | ↗ |
| 23 | 2021 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 375.0K | 61.9K | — | 1.16M | — | 11.4K | 1.61M | 72.21% | ↗ |
| 24 | 2021 | Matthew David Executive Vice President and Chief Financial Officer | 351.9K | 75.9K | — | 951.9K | — | 43.6K | 1.42M | 66.88% | ↗ |
| 25 | 2021 | John Armstrong Former Executive Vice President for Technical Operations | 272.5K | — | — | 742.9K | — | 323.9K | 1.34M | 55.47% | ↗ |
| 26 | 2021 | Elizabeth Hurlburt Executive Vice President and Head of Clinical Operations | 310.8K | 37.8K | — | 742.9K | — | 44.8K | 1.14M | 65.38% | ↗ |
| 27 | 2021 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 310.8K | 37.8K | — | 742.9K | — | 44.8K | 1.14M | 65.38% | ↗ |
| 28 | 2020 | Khoso Baluch Chief Executive Officer | 425.0K | — | — | 428.6K | 340.0K | 40.1K | 1.23M | 34.74% | ↗ |
| 29 | 2020 | Khoso Baluch Former Chief Executive Officer | 425.0K | — | — | 428.6K | 340.0K | 40.1K | 1.23M | 34.74% | ↗ |
| 30 | 2020 | Matthew David Executive Vice President and Chief Financial Officer | 209.4K | — | — | 768.4K | 99.0K | 20.9K | 1.10M | 70.00% | ↗ |
| 31 | 2020 | Matthew David Chief Financial Officer | 209.4K | — | — | 768.4K | 99.0K | 20.9K | 1.10M | 70.00% | ↗ |
| 32 | 2020 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance, Legal and Technical Operations | 350.0K | — | — | 408.1K | 163.3K | 9.7K | 931.1K | 43.82% | ↗ |
| 33 | 2020 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 350.0K | — | — | 408.1K | 163.3K | 9.7K | 931.1K | 43.82% | ↗ |
| 34 | 2020 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 291.8K | — | — | 332.4K | 136.5K | 35.6K | 796.3K | 41.75% | ↗ |
| 35 | 2020 | John Armstrong Executive Vice President for Technical Operations | 322.6K | — | — | 332.4K | 112.9K | 19.4K | 787.3K | 42.22% | ↗ |
| 36 | 2020 | John Armstrong Former Executive Vice President for Technical Operations | 322.6K | — | — | 332.4K | 112.9K | 19.4K | 787.3K | 42.22% | ↗ |
| 37 | 2020 | Robert W. Cook Chief Financial Officer | 242.4K | — | — | — | — | 2.6K | 18.00 | 0.00% | ↗ |
| 38 | 2019 | Khoso Baluch Chief Executive Officer | 387.9K | — | — | 1.13M | 248.0K | 26.3K | 1.80M | 63.12% | ↗ |
| 39 | 2019 | Phoebe Mounts Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | 232.9K | — | — | 426.8K | 84.0K | 2.5K | 746.2K | 57.20% | ↗ |
| 40 | 2019 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 280.0K | — | — | 298.5K | 67.2K | 25.7K | 671.4K | 44.46% | ↗ |
| 41 | 2019 | Robert W. Cook Chief Financial Officer | 350.0K | — | — | 127.1K | — | 20.8K | 497.9K | 25.53% | ↗ |
| 42 | 2019 | John Armstrong Executive Vice President for Technical Operations | 310.0K | — | — | 57.2K | 86.8K | 11.0K | 465.0K | 12.30% | ↗ |
| 43 | 2018 | Khoso Baluch Chief Executive Officer | 375.0K | — | — | — | 240.0K | 22.8K | 637.8K | 0.00% | ↗ |
| 44 | 2018 | Robert W. Cook Chief Financial Officer | 350.0K | — | — | — | 84.0K | 23.5K | 457.5K | 0.00% | ↗ |
| 45 | 2018 | Elizabeth Masson Executive Vice President and Head of Clinical Operations | 277.3K | — | — | 65.4K | 56.0K | 21.7K | 420.5K | 15.56% | ↗ |
| 46 | 2018 | Elizabeth Masson-Hurlburt Executive Vice President and Head of Clinical Operations | 277.2K | — | — | 65.4K | 56.0K | 21.7K | 420.5K | 15.56% | ↗ |
| 47 | 2018 | John Armstrong Executive Vice President for Technical Operations | 312.3K | — | — | — | 86.8K | — | 399.1K | 0.00% | ↗ |
| 48 | 2017 | Robert W. Cook Chief Financial Officer | 320.4K | — | — | 455.9K | 60.6K | 24.3K | 861.2K | 52.94% | ↗ |
| 49 | 2017 | Judith Abrams Chief Medical Officer | 346.7K | — | — | 455.9K | — | 15.4K | 818.1K | 55.73% | ↗ |
| 50 | 2017 | John Armstrong Executive Vice President for Technical Operations | 341.1K | — | 78.6K | 167.0K | 57.0K | — | 643.6K | 38.16% | ↗ |
| 51 | 2017 | Khoso Baluch Chief Executive Officer | 375.0K | — | — | — | 189.0K | 68.5K | 632.5K | 0.00% | ↗ |
| 52 | 2017 | James Altland Interim Chief Financial Officer | 57.1K | — | — | — | — | — | 57.1K | 0.00% | ↗ |
| 53 | 2017 | Elizabeth Masson Executive Vice President and Head of Clinical Operations | 2.8K | — | — | — | — | — | 2.8K | 0.00% | ↗ |
| 54 | 2016 | Khoso Baluch Chief Executive Officer | 93.8K | — | — | 3.19M | 75.0K | 39.6K | 3.39M | 93.86% | ↗ |
| 55 | 2016 | John Armstrong Executive Vice President for Technical Operations | 335.4K | — | — | 1.15M | — | — | 1.49M | 77.43% | ↗ |
| 56 | 2016 | Randy Milby Chief Executive Officer | 308.7K | — | — | — | 112.5K | 30.8K | 452.1K | 0.00% | ↗ |
| 57 | 2016 | Antony E. Pfaffle Chief Scientific Officer | 276.0K | — | — | — | — | 26.6K | 302.6K | 0.00% | ↗ |
| 58 | 2016 | James Altland Interim Chief Financial Officer | 244.5K | — | — | — | — | — | 244.5K | 0.00% | ↗ |
| 59 | 2015 | Randy Milby Chief Executive Officer | 300.0K | — | — | 269.0K | 150.0K | 4.7K | 723.7K | 37.17% | ↗ |
| 60 | 2015 | Antony E. Pfaffle Chief Scientific Officer | 250.0K | — | — | 269.0K | 75.0K | 6.7K | 600.7K | 44.78% | ↗ |
| 61 | 2015 | Harry O’Grady Chief Financial Officer | 183.0K | — | — | — | 73.6K | 3.6K | 260.2K | 0.00% | ↗ |
| 62 | 2015 | James Altland Interim Chief Financial Officer | 60.7K | — | — | — | — | — | 60.7K | 0.00% | ↗ |
| 63 | 2014 | Antony E. Pfaffle Acting Chief Scientific Officer | 219.8K | 30.0K | — | 356.6K | — | 16.9K | 623.7K | 57.16% | ↗ |
| 64 | 2014 | Antony E. Pfaffle Chief Scientific Officer | 219.8K | — | — | 356.6K | 30.0K | 16.9K | 623.7K | 57.16% | ↗ |
| 65 | 2014 | Randy Milby Chief Executive Officer | 287.5K | — | — | 147.5K | — | — | 435.0K | 33.91% | ↗ |
| 66 | 2014 | Randy Milby Chief Executive Officer | 287.5K | — | — | 147.5K | — | — | 435.0K | 33.91% | ↗ |
| 67 | 2014 | Steven W. Lefkowitz Interim Chief Financial Officer | 60.0K | — | — | 339.3K | — | 26.5K | 425.7K | 79.69% | ↗ |
| 68 | 2014 | Harry O’Grady Chief Financial Officer | 103.8K | — | — | 111.0K | — | — | 214.8K | 51.68% | ↗ |
| 69 | 2014 | Harry O’Grady Chief Financial Officer | 103.8K | — | — | 111.0K | — | — | 214.8K | 51.68% | ↗ |
| 70 | 2013 | Randy Milby Chief Executive Officer | 223.5K | — | — | 368.5K | — | — | 592.0K | 62.25% | ↗ |
| 71 | 2013 | Randy Milby Chief Executive Officer | 223.5K | — | — | 147.5K | — | — | 435.0K | 33.91% | ↗ |
| 72 | 2013 | Antony E. Pfaffle Acting Chief Scientific Officer | 120.0K | — | — | 154.8K | — | 37.5K | 312.3K | 49.56% | ↗ |
| 73 | 2013 | Antony E. Pfaffle Chief Scientific Officer | 120.0K | — | — | 154.8K | — | 37.5K | 312.3K | 49.56% | ↗ |
| 74 | 2013 | Steven W. Lefkowitz Interim Chief Financial Officer | 30.0K | — | — | 88.4K | — | 39.7K | 158.1K | 55.94% | ↗ |
| 75 | 2013 | Richard M. Cohen Interim Chief Executive Officer and Interim Chief Financial Officer | 60.0K | — | — | 80.6K | — | — | 140.6K | 57.31% | ↗ |
| 76 | 2013 | Harry O’Grady Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 77 | 2012 | Mark A. Klausner, M.D. Chief Medical Officer | 180.8K | — | — | — | — | 7.6K | 188.4K | 0.00% | ↗ |
| 78 | 2012 | Officer and Chief Financial Officer, Treasurer and Secretary | 93.8K | — | — | 71.2K | — | 18.0K | 182.9K | 38.92% | ↗ |
| 79 | 2012 | Randy Milby Chief Executive Officer | 58.8K | — | — | 67.8K | — | — | 126.6K | 53.54% | ↗ |
| 80 | 2012 | Randy Milby Chief Operating Officer | 58.8K | — | — | 67.8K | — | — | 126.6K | 53.54% | ↗ |
| 81 | 2012 | Richard M. Cohen Interim Chief Executive Officer and Interim Chief Financial Officer | 86.3K | — | — | 39.2K | — | — | 125.5K | 31.25% | ↗ |
| 82 | 2012 | Interim Chief Executive Officer | 86.3K | — | — | 39.2K | — | — | 125.5K | 31.25% | ↗ |
| 83 | 2012 | Antony E. Pfaffle Acting Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 84 | 2012 | Steven W. Lefkowitz Interim Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 85 | 2011 | Mark A. Klausner, M.D. Chief Medical Officer | 258.3K | — | — | 453.0K | — | — | 711.3K | 63.68% | ↗ |
| 86 | 2011 | Mark A. Klausner, M.D. Chief Medical Officer | 258.3K | — | — | 453.0K | — | — | 711.3K | 63.68% | ↗ |
| 87 | 2011 | John C. Houghton Former President and Chief Executive Officer | 350.0K | — | — | — | — | — | 350.0K | 0.00% | ↗ |
| 88 | 2011 | Officer and Chief Financial Officer, Treasurer and Secretary | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 89 | 2011 | Brian Lenz Former Chief Operating Officer and Chief Financial | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 90 | 2011 | Richard M. Cohen Interim Chief Executive Officer and Interim Chief Financial Officer | 54.0K | — | — | 50.9K | — | — | 104.9K | 48.52% | ↗ |
| 91 | 2011 | Interim Chief Executive Officer | 22.5K | — | — | 50.9K | — | 31.5K | 104.9K | 48.52% | ↗ |
| 92 | 2011 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 36.7K | — | — | — | — | — | 36.7K | 0.00% | ↗ |
| 93 | 2011 | Randy Milby Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 94 | 2010 | John C. Houghton President and Chief Executive Officer | 250.0K | 108.5K | — | 2.05M | — | — | 2.41M | 85.10% | ↗ |
| 95 | 2010 | John C. Houghton Former President and Chief Executive Officer | 250.0K | 108.5K | — | 2.05M | — | — | 2.41M | 85.10% | ↗ |
| 96 | 2010 | Mark T. Houser, M.D. Former Chief Medical Officer | 220.0K | 51.1K | — | 818.8K | — | — | 1.09M | 75.13% | ↗ |
| 97 | 2010 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 220.0K | 51.1K | — | 818.8K | — | — | 1.09M | 75.13% | ↗ |
| 98 | 2010 | Brian Lenz Former Chief Operating Officer and Chief Financial | 175.0K | 84.8K | — | 818.8K | — | — | 1.08M | 75.92% | ↗ |
| 99 | 2010 | Brian Lenz Chief Financial Officer, Treasurer and Secretary | 175.0K | 84.8K | — | 818.8K | — | — | 1.08M | 75.92% | ↗ |
| 100 | 2009 | John C. Houghton President and Chief Executive Officer | 222.5K | 75.0K | — | — | — | — | 297.5K | 0.00% | ↗ |
| 101 | 2009 | John C. Houghton Former President and Chief Executive Officer | 222.5K | 75.0K | — | — | — | — | 297.5K | 0.00% | ↗ |
| 102 | 2009 | Mark T. Houser, M.D. Former Chief Medical Officer Randy Milby | 220.0K | — | — | — | — | — | 220.0K | 0.00% | ↗ |
| 103 | 2009 | Mark T. Houser, M.D. Former Chief Medical Officer | 220.0K | — | — | — | — | — | 220.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph Todisco | CEO & Chairman of the Board of Directors | 2M | male |
| Kaufman Beth Zelnick | EVP, Chief Legal and Compliance Officer & Corporate Secretary | 981.6K | female |
| Elizabeth Hurlburt | Executive Vice President, Chief Operating Officer & Chief Integration Officer | 959.4K | female |
| Matthew T. David | EVP & Chief Business Officer | 634.9K | — |
| Susan Blum | Executive Vice President & Chief Financial Officer | 634.9K | female |
| Michael Seckler | Executive Vice President & Chief Commercial Officer | 561.6K | male |
| Tushar Mukherjee | Senior Vice President & Head of Technical Operations | — | — |
| Donna Ucci | Senior Vice President & Head of Global Quality | — | — |
| Jared L. Crandon | Executive Director of Clinical Portfolio Management | — | male |
| Peter Sullivan BCOP | Senior Vice President of Market Access | — | — |
| Beth Steinbrenner | SVP & Chief Human Resource Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
